Medix Biochemica Acquires German Immunoassay Solutions Developer Candor Bioscience

Medix Biochemica (Espoo, Finland), a global leader in the supply of critical raw materials for the in vitro diagnostics (IVD) industry, has acquired CANDOR Bioscience GmbH (Allgäu, Germany), a developer and manufacturer of premium immunoassay solutions.

Medix Biochemica is a market-leading, independent supplier of critical raw materials to the IVD industry worldwide. The company develops, produces, and supplies high-quality antibodies, antigens, and other critical IVD raw material products to IVD companies worldwide, enabling the delivery of accurate IVD tests to billions of patients. CANDOR Bioscience is a provider of a comprehensive selection of premium solutions for immunoassays, including HAMA and interference blockers, surface blockers, stabilizers, and buffer solutions. By using CANDOR Bioscience’s solutions, immunoassay manufacturers can improve reliability of test results, simplify assay designs and reduce process times. The acquisition of CANDOR Bioscience both strengthens Medix Biochemica’s range of high-quality raw materials to the worldwide IVD industry and enhances its capabilities to support test manufacturers in immunoassay development.

“We are delighted to welcome CANDOR into the Medix Biochemica family,” said Steve Ferguson, CEO of Medix Biochemica. “The partnership with CANDOR strengthens Medix Biochemica’s ability to support our customer base by adding complementary expertise in immunoassay development and broadening our offering of critical IVD raw materials with a leading portfolio of premium blockers and stabilizers. Together, we will continue to provide the highest quality raw materials that enable diagnostic innovation, and we look forward to a successful collaboration with the CANDOR team.”

“Joining forces with Medix Biochemica is an exciting milestone for CANDOR,” added Dr. Tobias Polifke and Dr. Peter Rauch, co-founders and Managing Directors of CANDOR Bioscience. “We are proud of our legacy in providing differentiated, high-performance solutions for immunoassay development, and we share Medix Biochemica’s commitment to quality and innovation. By combining our capabilities and offerings, we will be better positioned to support the evolving needs of our customers. Medix Biochemica’s products, including antibodies and quality control materials, perfectly complement our solutions, enhancing the value we offer to partners in the IVD industry.”

Related Links:
Medix Biochemica
CANDOR Bioscience GmbH

Visit expo >

Gold Member

Troponin T QC

Troponin T Quality Control

Verification Panels for Assay Development & QC
Seroconversion Panels

New

Chagas Disease Test

LIAISON Chagas

New

Ultra-Low Temperature Freezer

iUF118-GX